|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular epidemiology and functional assessment of novel allelic variants of SLC26A4in nonsyndromic hearing loss patients with enlarged vestibular aqueduct in China显示文摘 | Yuan YY Guo WW Tang J | 2012 | PLoS One2012，7，49： | 1 |
| 2 | Helicobacter pylori infection and risk of gastric cancer in Shanghai, China:updated results based upon a locally developed and validated assay and further follow-up of the cohort显示文摘 | Yuan JM Yu MC Xu WW | 1999 | Cancer Epidemiol Biomark Pre1999，8，： | 1 |
| 3 | Cigarette smoking in China: public health, science, and policy 显示文摘 | AU WW SUDS YUAN J | 2012 | Rev Environ Health2012，27，1： | 1 |
| 4 | Helicohacter pylori infection and risk of gastric cancer in Shanghai, China: updated resultsbased upon a locally developed and validated assay and further follow-up of the cohort 显示文摘 | Yuan JM Yu MC Xu WW | 1999 | Cancer Epidemiol Biomarkers &Prev1999，8，： | 1 |
| 5 | Determination and pharmaco- kinetics of DT-13 in rat plasma by LC-MS 显示文摘 | Chen LL Yuan WW Hu ZF | 2011 | J Pharmaceut Biomed Anal2011，6，： | 1 |
| 6 | Studies of UPLC fingerprint for the identification of Magnoliae Officinalis Cortex processed显示文摘 | Wang L Yuan K Yu WW | 2010 | Pharmacogn Mag2010，6，22： | 1 |
| 7 | Human ICE/CED-3 protease nomenclature显示文摘 | Livingston DJ Nicholson DW Salvesen G Thornberry NA Wong WW and Yuan J(1996) | 1996 | Cell1996，171，： | 1 |
| 8 | A simple colorimetric method to detect biological evidence of human exposure to microcystins显示文摘 | Hilborn ED Carmichael WW Yuan M | | 0，，02： | 1 |
| 9 | Determination and pharmacokinetics of DT-13 in rat plasma by LC-MS显示文摘 | Chen LL Yuan WW Hu ZF | | 0，，03： | 1 |
| 10 | Antioxidant activity and cytoprotective effect of κ-carrageenan oligosaccharides and their different derivatives显示文摘 | Yuan HM Song JM Zhang WW | 2006 | Bioorganic & Medicinal Chemistry Letters2006，16，5： | 1 |
| 11 | Association of GSTP1 and RRM1 polymorphisms with the response and toxicity of Gemcitabine-cisplatin combination chemotherapy in Chinese patients with non-small cell lung cancer 显示文摘 | Yuan ZJ Zhou WW Liu W | 2015 | Asian Pac J Cancer Prey2015，16，0： | 1 |
| 12 | Human health effects workgroup poster abstracts-serologic evaluation of human microcystin exposure 显示文摘 | Hilbom ED Carmichael WW Yuan M | 2008 | Cyanobacterial Harmful Algal Blooms:State of the Seience and Research Needs2008，619，： | 1 |
| 13 | Cytokeratin 12 in human ocular surface epithelia is the antigen reactive with a commercial anti-Galpha q antibody显示文摘 | Boehlke CS Yuan C Kao WW | 2004 | Mol Vis2004，16，10： | 1 |
| 14 | Genistein as a neuroprotective antioxidant attenuates redox imbalance induced by β-amyloidpeptides 25-35 in PC 12 cells 显示文摘 | Ma WW Yuan LH Yu HL | 2010 | Int J Neurosci2010，28，4： | 1 |
| 15 | Association of GSTP1 and RRM1 polymorphisms with the response and toxicity of gemcit- abine- cisplatin combination chemotherapy in chinese patients with non -small cell lung cancer显示文摘 | Yuan Z J Zhou WW Liu W | 2015 | Asian Pac J Cancer Prey2015，16，10： | 1 |
| 16 | Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States显示文摘BACKGROUND As Hepatitis C virus infection(HCV+)rates in kidney donors and transplant recipients rise,direct-acting antivirals(DAA)may affect outcomes.AIM To analyze the effects of HCV+in donors,recipients,or both,on deceased-donor(DD)kidney transplantation(KT)outcomes,and the impact of DAAs on those effects.METHODS The Organ Procurement and Transplantation Network data of adult first solitary DD-KT recipients 1994-2019 were allocated into four groups by donor and recipient HCV+status.We performed patient survival(PS)and death-censored graft survival(DCGS)pairwise comparisons after propensity score matching to assess the effects of HCV+in donors and/or recipients,stratifying our study by DAA era to evaluate potential effect modification.RESULTS Pre-DAA,for HCV+recipients,receiving an HCV+kidney was associated with 1.28-fold higher mortality(HR 1.151.281.42)and 1.22-fold higher death-censored graft failure(HR 1.081.221.39)compared to receiving an HCV-kidney and the absolute risk difference was 3.3%(95%CI:1.8%-4.7%)for PS and 3.1%(95%CI:1.2%-5%)for DCGS at 3 years.The HCV dual-infection(donor plus recipient)group had worse PS(0.56-fold)and DCGS(0.71-fold)than the dual-uninfected.Donor HCV+derived worse post-transplant outcomes than recipient HCV+(PS 0.36-fold,DCGS 0.34-fold).In the DAA era,the risk associated with HCV+in donors and/or recipients was no longer statistically significant,except for impaired PS in the dual-infected vs dual-uninfected(0.43-fold).CONCLUSION Prior to DAA introduction,donor HCV+negatively influenced kidney transplant outcomes in all recipients,while recipient infection only relatively impaired outcomes for uninfected donors.These adverse effects disappeared with the introduction of DAA. | Qing Yuan Shanjuan Hong Gregory Leya Eve Roth Georgios Tsoulfas WW Williams Joren C Madsen Nahel Elias | 2023 | World Journal of Transplantation2023，13，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员